{"id":7,"date":"2026-04-03T15:06:42","date_gmt":"2026-04-03T22:06:42","guid":{"rendered":"https:\/\/www.kalonahealth.com\/?page_id=7"},"modified":"2026-04-03T15:21:08","modified_gmt":"2026-04-03T22:21:08","slug":"7-2","status":"publish","type":"page","link":"https:\/\/www.kalonahealth.com\/?page_id=7","title":{"rendered":"Biktarvy Cost 2026: What You Pay With or Without Insurance | KalonaHealth"},"content":{"rendered":"\n<!--\n==========================================================\nKOLANAHEALTH.COM \u2014 \/biktarvy-cost\/\nSINGLE CUSTOM HTML BLOCK \u2014 schema + CSS + HTML\n\nMASTER TEMPLATE v1.0 \u2014 2026-04-04\n  This file is the source of truth for all KH content pages.\n  CSS lives here only \u2014 no theme overrides, no page builder.\n  Astra handles: body font stack, base line-height, page bg,\n  container max-width, and overall link color inheritance.\n  This block handles: component styling only.\n\nSEO TITLE:\n  Biktarvy Cost 2026: What You Pay With or Without\n  Insurance | Kolana Health\n\nMETA DESCRIPTION:\n  Biktarvy's list price is $4,216\/month in 2026 \u2014 but most\n  patients pay $0\u2013$5. See what you pay by coverage type,\n  how copay accumulators work, and every program that can\n  reduce your cost.\n\nPAGE URL: https:\/\/kolanahealth.com\/biktarvy-cost\/\n==========================================================\n-->\n\n\n<!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n<!-- SCHEMA 1 OF 3 \u2014 MedicalWebPage                         -->\n<!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n<script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"MedicalWebPage\",\n  \"url\": \"https:\/\/kolanahealth.com\/biktarvy-cost\/\",\n  \"name\": \"Biktarvy Cost: What Patients Pay in 2026\",\n  \"description\": \"A comprehensive breakdown of Biktarvy cost in 2026, including list price, insurance costs, copay card eligibility, Medicare Part D, patient assistance programs, and how to access Biktarvy at low or no cost.\",\n  \"datePublished\": \"2024-06-01\",\n  \"dateModified\": \"2026-04-04\",\n  \"lastReviewed\": \"2026-04-04\",\n  \"inLanguage\": \"en-US\",\n  \"medicalAudience\": { \"@type\": \"MedicalAudience\", \"audienceType\": \"Patient\" },\n  \"author\": {\n    \"@type\": \"Person\",\n    \"name\": \"Ray Ashton\",\n    \"url\": \"https:\/\/kolanahealth.com\/ray-ashton\/\"\n  },\n  \"reviewedBy\": {\n    \"@type\": \"Person\",\n    \"name\": \"Dr. Neha Mishra MD\",\n    \"url\": \"https:\/\/kolanahealth.com\/dr-neha-mishra\/\"\n  },\n  \"isPartOf\": {\n    \"@type\": \"WebSite\",\n    \"name\": \"Kolana Health\",\n    \"url\": \"https:\/\/kolanahealth.com\"\n  },\n  \"publisher\": {\n    \"@type\": \"Organization\",\n    \"name\": \"Kolana Health\",\n    \"url\": \"https:\/\/kolanahealth.com\",\n    \"logo\": {\n      \"@type\": \"ImageObject\",\n      \"url\": \"https:\/\/kolanahealth.com\/wp-content\/uploads\/kolana-health-logo.png\",\n      \"width\": 250,\n      \"height\": 60\n    }\n  }\n}\n<\/script>\n\n\n<!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n<!-- SCHEMA 2 OF 3 \u2014 BreadcrumbList                         -->\n<!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n<script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"BreadcrumbList\",\n  \"itemListElement\": [\n    {\n      \"@type\": \"ListItem\",\n      \"position\": 1,\n      \"name\": \"Home\",\n      \"item\": \"https:\/\/kolanahealth.com\/\"\n    },\n    {\n      \"@type\": \"ListItem\",\n      \"position\": 2,\n      \"name\": \"HIV\",\n      \"item\": \"https:\/\/kolanahealth.com\/hiv\/\"\n    },\n    {\n      \"@type\": \"ListItem\",\n      \"position\": 3,\n      \"name\": \"Biktarvy Cost\",\n      \"item\": \"https:\/\/kolanahealth.com\/biktarvy-cost\/\"\n    }\n  ]\n}\n<\/script>\n\n\n<!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n<!-- SCHEMA 3 OF 3 \u2014 FAQPage                                -->\n<!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n<script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How much does Biktarvy cost without insurance in 2026?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Biktarvy's list price is $4,216 per month as of January 2026, with retail cash prices typically ranging from $3,800 to over $5,000. Most uninsured patients qualify for programs that reduce the cost to $0. See the full guide: https:\/\/kolanahealth.com\/biktarvy-cost-without-insurance\/\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How much does Biktarvy cost with insurance?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"With commercial insurance and Gilead's copay card, most patients pay $0 to $5 per month. Without the copay card, costs depend on your plan's formulary tier, deductible status, and coinsurance percentage. Medicare patients with Extra Help may pay $4 to $9 per month.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Why did my Biktarvy copay increase this month?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Common causes include annual deductible reset (especially in January), a formulary tier change by your insurer, or the adoption of a copay accumulator program that prevents manufacturer assistance from counting toward your deductible. Contact your insurer to confirm.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is prior authorization for Biktarvy and how long does it take?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Prior authorization is a requirement by some insurers for your prescriber to submit clinical justification before the plan covers Biktarvy. Standard decisions typically take 5 to 15 business days. Urgent requests may be processed within 24 to 72 hours. About 98% of insured patients can access Biktarvy without prior authorization or step therapy.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How do Biktarvy copay cards work and who is eligible?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Gilead's Advancing Access copay card reduces out-of-pocket costs for commercially insured patients, typically to $0 per month with a $7,200 annual cap. It does not apply to Medicare, Medicaid, TRICARE, or other government-funded insurance. Be aware that some plans use copay accumulator programs that prevent this assistance from counting toward your deductible.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is a copay accumulator and how does it affect my Biktarvy cost?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"A copay accumulator prevents third-party payments (like manufacturer copay cards) from counting toward your deductible or out-of-pocket maximum. After the copay card's $7,200 annual cap is exhausted, you may owe your full remaining deductible. More than 19 states have enacted laws restricting these programs. Ask your insurer if your plan uses one.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What if my insurance denies coverage for Biktarvy?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Request a written explanation of the denial, then ask your prescriber's office to file a formal appeal with lab results, treatment history, and clinical guidelines. Most plans must resolve appeals within 30\u201360 days. The Patient Advocate Foundation offers free case management to help.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Can I safely stop taking Biktarvy if I cannot afford it?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Do not stop antiretroviral therapy without speaking with your clinician. Interrupting treatment can lead to viral rebound, immune decline, and drug resistance. If cost is a barrier, contact your prescriber immediately \u2014 emergency fills and assistance programs can often be arranged within days.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is there a generic version of Biktarvy in the United States?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"No. As of 2026, no FDA-approved generic exists. Patent expiry is not before November 2036. Generic versions exist in some countries under Gilead's voluntary licensing program, but are not approved for U.S. distribution.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What if I lose my job and health insurance?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Contact your state ADAP program and local Ryan White clinic immediately \u2014 these exist specifically for this situation. You may also qualify for Gilead's PAP for uninsured individuals. COBRA continuation may be available but is often expensive. Use findhivcare.hrsa.gov to locate your nearest clinic.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Will the Medicare price negotiation lower my Biktarvy cost?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Biktarvy was selected for Medicare price negotiations in January 2026 \u2014 the first HIV drug ever chosen. A negotiated price applies only to Medicare Part D and is expected in 2028 at the earliest. It will not affect commercial insurance or uninsured cash prices.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Can I change pharmacies to lower my Biktarvy cost?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Possibly. Switching to an in-network or plan-preferred pharmacy can reduce your cost, and some plans offer lower cost-sharing for 90-day mail-order fills. Call your insurer to confirm which pharmacies are preferred. If you receive care at a 340B-eligible clinic, ask if your prescription can be filled through their pharmacy.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is 340B pricing and can it lower my Biktarvy cost?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"The 340B program requires manufacturers to sell drugs at reduced prices to eligible safety-net providers, including Ryan White clinics and FQHCs. If you receive care at a participating facility, you may benefit from lower medication costs. Ask your clinic if they participate.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Are there nonprofit foundations that help pay for Biktarvy?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Yes. The Patient Advocate Foundation, PAN Foundation, and HealthWell Foundation all offer HIV copay assistance programs. These are especially important for Medicare patients who cannot use Gilead's copay card. Fund availability fluctuates \u2014 if one is closed, check others or apply for a waitlist.\"\n      }\n    }\n  ]\n}\n<\/script>\n\n\n<!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n<!-- FONTS \u2014 self-hosted via Google Fonts CDN with preload  -->\n<!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n<link rel=\"preconnect\" href=\"https:\/\/fonts.googleapis.com\">\n<link rel=\"preconnect\" href=\"https:\/\/fonts.gstatic.com\" crossorigin>\n<link href=\"https:\/\/fonts.googleapis.com\/css2?family=Source+Sans+3:ital,wght@0,400;0,600;0,700;1,400&#038;family=Source+Serif+4:ital,wght@0,400;0,600;0,700;1,400&#038;display=swap\" rel=\"stylesheet\">\n\n\n<!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n<!-- CSS \u2014 COMPONENT STYLES ONLY                            -->\n<!-- Astra handles: body, container, base links, bg color   -->\n<!-- This block handles: every KH-specific component        -->\n<!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n<style>\n\/* \u2500\u2500 RESET (scoped to .kh wrapper only) \u2500\u2500 *\/\n.kh *, .kh *::before, .kh *::after { box-sizing: border-box; margin: 0; padding: 0; }\n\n\/* \u2500\u2500 DESIGN TOKENS \u2500\u2500 *\/\n:root {\n  --kh-ink:          #1b2332;\n  --kh-body:         #3d4a5c;\n  --kh-muted:        #535f6e;\n  --kh-border:       #dce3eb;\n  --kh-bg:           #f6f8fb;\n  --kh-accent:       #1a6b5a;\n  --kh-accent-light: #e8f5f1;\n  --kh-accent-link:  #b2d8cf;\n  --kh-warn:         #b45309;\n  --kh-warn-bg:      #fffbeb;\n  --kh-danger:       #b91c1c;\n  --kh-danger-bg:    #fef2f2;\n  --kh-serif:        \"Source Serif 4\", Georgia, \"Times New Roman\", serif;\n  --kh-sans:         \"Source Sans 3\", -apple-system, BlinkMacSystemFont, \"Segoe UI\", sans-serif;\n}\n\n\/* \u2500\u2500 WRAPPER \u2500\u2500 *\/\n.kh {\n  max-width: 720px;\n  margin: 0 auto;\n  font-family: var(--kh-serif);\n  color: var(--kh-body);\n  line-height: 1.78;\n  font-size: 18px;\n  padding: 0 20px;\n}\n\n\/* \u2500\u2500 LINKS \u2500\u2500 *\/\n.kh a { color: var(--kh-accent); text-decoration: underline; text-decoration-color: var(--kh-accent-link); text-underline-offset: 3px; }\n.kh a:hover { text-decoration-color: var(--kh-accent); }\n\n\/* \u2500\u2500 HEADINGS \u2500\u2500 *\/\n.kh h2 { font-family: var(--kh-sans); font-size: 22px; line-height: 1.3; font-weight: 700; color: var(--kh-ink); margin: 48px 0 16px; padding-bottom: 10px; border-bottom: 2px solid var(--kh-border); }\n.kh h3 { font-family: var(--kh-sans); font-size: 18px; font-weight: 700; color: var(--kh-ink); margin: 28px 0 8px; }\n.kh h4 { font-family: var(--kh-sans); font-size: 15px; font-weight: 700; color: var(--kh-accent); margin: 20px 0 6px; text-transform: uppercase; letter-spacing: 0.5px; }\n\n\/* \u2500\u2500 BODY TEXT \u2500\u2500 *\/\n.kh p { margin: 0 0 18px; }\n.kh ul, .kh ol { padding-left: 24px; margin: 8px 0 18px; }\n.kh li { margin-bottom: 6px; }\n.kh strong { color: var(--kh-ink); }\n.kh em { font-style: italic; }\n.kh blockquote { margin: 24px 0; padding: 16px 24px; background: var(--kh-bg); border-left: 4px solid var(--kh-muted); font-style: italic; color: var(--kh-body); border-radius: 0 6px 6px 0; }\n\n\/* \u2500\u2500 AVATAR \u2500\u2500 *\/\n.kh-avatar { border-radius: 50%; overflow: hidden; flex-shrink: 0; background-size: cover; background-position: center top; box-shadow: 0 0 0 1px var(--kh-border); display: block; }\n.kh-avatar-44 { width: 44px; height: 44px; }\n.kh-avatar-36 { width: 36px; height: 36px; }\n\n\/* \u2500\u2500 BYLINE \u2500\u2500 *\/\n.kh-byline { display: flex; align-items: center; gap: 16px; margin: 0 0 20px; font-family: var(--kh-sans); font-size: 14px; color: var(--kh-muted); line-height: 1.6; flex-wrap: wrap; }\n.kh-byline-pair { display: flex; align-items: center; gap: 8px; flex-shrink: 0; }\n.kh-byline a { color: var(--kh-ink); font-weight: 700; text-decoration: none; }\n.kh-byline a:hover { text-decoration: underline; }\n.kh-byline-sep { color: var(--kh-border); margin: 0 4px; }\n\n\/* \u2500\u2500 DISCLOSURE \u2500\u2500 *\/\n.kh-disclosure { font-family: var(--kh-sans); font-size: 14px; line-height: 1.6; color: var(--kh-muted); background: var(--kh-bg); border: 1px solid var(--kh-border); border-radius: 6px; padding: 14px 18px; margin: 0 0 32px; }\n.kh-ep-link { display: flex; align-items: center; font-size: 14px; line-height: 1; margin-top: 8px; }\n\n\/* \u2500\u2500 PRICE SNAPSHOT \u2500\u2500 *\/\n.kh-snapshot { background: var(--kh-bg); border: 1px solid var(--kh-border); border-radius: 10px; padding: 20px 24px; margin: 24px 0; font-family: var(--kh-sans); }\n.kh-snapshot-title { font-weight: 700; font-size: 15px; color: var(--kh-accent); text-transform: uppercase; letter-spacing: 0.6px; margin-bottom: 14px; }\n.kh-snapshot-grid { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }\n.kh-snapshot-item { padding: 10px 14px; background: #fff; border-radius: 6px; border: 1px solid #eef1f5; }\n.kh-snapshot-label { font-size: 13px; color: var(--kh-muted); margin-bottom: 2px; }\n.kh-snapshot-value { font-size: 20px; font-weight: 700; color: var(--kh-ink); }\n.kh-snapshot-value small { font-size: 13px; font-weight: 400; color: var(--kh-muted); }\n.kh-snapshot-note { font-size: 13px; color: var(--kh-muted); margin-top: 12px; padding-top: 10px; border-top: 1px solid #eef1f5; }\n\n\/* \u2500\u2500 CALLOUT BOXES \u2500\u2500 *\/\n.kh-callout { font-family: var(--kh-sans); border-radius: 6px; padding: 16px 20px; margin: 24px 0; font-size: 15px; line-height: 1.6; }\n.kh-callout p { font-size: 15px; margin-bottom: 10px; }\n.kh-callout p:last-child { margin-bottom: 0; }\n.kh-callout ul { font-size: 15px; }\n.kh-callout-warn { background: var(--kh-warn-bg); border-left: 4px solid var(--kh-warn); }\n.kh-callout-danger { background: var(--kh-danger-bg); border-left: 4px solid var(--kh-danger); }\n.kh-callout-info { background: var(--kh-accent-light); border-left: 4px solid var(--kh-accent); }\n\n\/* \u2500\u2500 KEY FACTS \u2500\u2500 *\/\n.kh-keyfacts { background: var(--kh-bg); border: 1px solid var(--kh-border); border-radius: 8px; padding: 20px 24px; margin: 24px 0; font-family: var(--kh-sans); font-size: 15px; line-height: 1.6; }\n.kh-keyfacts-title { font-weight: 700; font-size: 14px; text-transform: uppercase; letter-spacing: 0.8px; color: var(--kh-accent); margin-bottom: 10px; }\n.kh-keyfacts ul { padding-left: 18px; margin: 0; }\n.kh-keyfacts li { margin-bottom: 6px; color: var(--kh-body); }\n\n\/* \u2500\u2500 TABLE \u2500\u2500 *\/\n.kh-table-wrap { overflow-x: auto; -webkit-overflow-scrolling: touch; margin: 20px 0 24px; border-radius: 8px; border: 1px solid var(--kh-border); }\n.kh table { width: 100%; border-collapse: collapse; font-family: var(--kh-sans); font-size: 15px; min-width: 480px; }\n.kh th { background: var(--kh-ink); color: #fff; padding: 12px 16px; text-align: left; font-weight: 600; font-size: 13px; text-transform: uppercase; letter-spacing: 0.4px; }\n.kh td { padding: 12px 16px; border-bottom: 1px solid #eef1f5; vertical-align: top; }\n.kh tr:nth-child(even) td { background: var(--kh-bg); }\n.kh tr:hover td { background: var(--kh-accent-light); }\n.kh-table-note { font-family: var(--kh-sans); font-size: 14px; color: var(--kh-muted); font-style: italic; margin: -16px 0 24px; }\n\n\/* \u2500\u2500 FAQ \u2500\u2500 *\/\n.kh-faq { margin: 24px 0; }\n.kh-faq-item { padding: 16px 0; border-bottom: 1px solid var(--kh-border); }\n.kh-faq-item:last-child { border-bottom: none; }\n.kh-faq-q { font-family: var(--kh-sans); font-weight: 700; font-size: 17px; color: var(--kh-ink); margin-bottom: 8px; }\n.kh-faq-a { margin: 0; font-size: 16px; }\n\n\/* \u2500\u2500 CHECKLIST \u2500\u2500 *\/\n.kh-checklist { background: var(--kh-accent-light); border: 1px solid var(--kh-accent-link); border-radius: 8px; padding: 20px 24px; margin: 28px 0; font-family: var(--kh-sans); }\n.kh-checklist-title { font-weight: 700; font-size: 16px; color: var(--kh-accent); margin-bottom: 12px; }\n.kh-checklist ul { list-style: none; padding-left: 0; margin: 0; }\n.kh-checklist li { padding: 5px 0 5px 28px; position: relative; font-size: 15px; color: var(--kh-body); }\n.kh-checklist li::before { content: '\\2610'; position: absolute; left: 0; color: var(--kh-accent); font-size: 16px; }\n\n\/* \u2500\u2500 CROSSLINK \u2500\u2500 *\/\n.kh-crosslink { background: var(--kh-bg); border: 1px solid var(--kh-border); border-left: 4px solid var(--kh-accent); border-radius: 0 8px 8px 0; padding: 16px 20px; margin: 24px 0; font-family: var(--kh-sans); font-size: 15px; line-height: 1.6; }\n.kh-crosslink strong { display: block; margin-bottom: 4px; color: var(--kh-ink); font-size: 15px; }\n\n\/* \u2500\u2500 HOW WE REVIEWED \u2500\u2500 *\/\n.kh-reviewed { border-top: 2px solid var(--kh-border); padding: 16px 0; margin-top: 36px; font-family: var(--kh-sans); }\n.kh-reviewed-byline { display: flex; align-items: center; gap: 12px; margin-bottom: 14px; font-size: 14px; color: var(--kh-muted); flex-wrap: wrap; }\n.kh-reviewed-byline .kh-byline-pair { gap: 8px; }\n.kh-reviewed-byline a { color: var(--kh-ink); font-weight: 700; text-decoration: none; }\n.kh-reviewed-byline a:hover { text-decoration: underline; }\n.kh-reviewed-body { font-size: 14px; line-height: 1.6; color: var(--kh-muted); padding-top: 12px; border-top: 1px solid #eef1f5; }\n.kh-reviewed-body p { font-size: 14px; margin: 0 0 6px; }\n\n\/* \u2500\u2500 REFERENCES \u2500\u2500 *\/\n.kh-refs { font-family: var(--kh-sans); font-size: 13px; line-height: 1.6; color: var(--kh-muted); margin-top: 32px; padding-top: 20px; border-top: 1px solid var(--kh-border); }\n.kh-refs h2 { font-size: 16px; border-bottom: none; margin: 0 0 10px; color: var(--kh-muted); }\n.kh-refs ol { padding-left: 18px; }\n.kh-refs li { margin-bottom: 5px; }\n\n\/* \u2500\u2500 MOBILE \u2014 600px \u2500\u2500 *\/\n@media (max-width: 600px) {\n  .kh { font-size: 17px; padding: 0 16px; }\n  .kh h2 { font-size: 20px; margin-top: 36px; }\n  .kh h3 { font-size: 17px; }\n  .kh-byline { gap: 8px; flex-direction: column; align-items: flex-start; }\n  .kh-byline-sep { display: none; }\n  .kh-avatar-44 { width: 36px; height: 36px; }\n  .kh-snapshot-grid { grid-template-columns: 1fr; }\n  .kh-snapshot-note { font-size: 12px; }\n  .kh-callout { padding: 14px 16px; }\n  .kh-keyfacts { padding: 16px 18px; }\n  .kh-checklist { padding: 16px 18px; }\n  .kh-faq-q { font-size: 16px; }\n  .kh table { font-size: 14px; min-width: 420px; }\n  .kh-refs { padding: 16px 0 0; }\n}\n\n\/* \u2500\u2500 SMALL SCREENS \u2014 375px \u2500\u2500 *\/\n@media (max-width: 375px) {\n  .kh { padding: 0 12px; }\n  .kh h2 { font-size: 18px; }\n  .kh h3 { font-size: 16px; }\n  .kh-snapshot-item { padding: 8px 10px; }\n  .kh-snapshot-value { font-size: 17px; }\n}\n<\/style>\n\n\n<!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n<!-- PAGE CONTENT                                           -->\n<!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n<div class=\"kh\">\n\n<!-- BYLINE -->\n<div class=\"kh-byline\">\n  <div class=\"kh-byline-pair\">\n    <div class=\"kh-avatar kh-avatar-44\" style=\"background-image:url('https:\/\/kolanahealth.com\/wp-content\/uploads\/2026\/03\/Dr-Neha-Mishra.jpg');\" role=\"img\" aria-label=\"Dr. Neha Mishra, MD\"><\/div>\n    <span>Medically reviewed by <a href=\"https:\/\/kolanahealth.com\/dr-neha-mishra\/\">Dr. Neha Mishra, MD<\/a><\/span>\n  <\/div>\n  <span class=\"kh-byline-sep\">&mdash;<\/span>\n  <div class=\"kh-byline-pair\">\n    <div class=\"kh-avatar kh-avatar-44\" style=\"background-image:url('https:\/\/kolanahealth.com\/wp-content\/uploads\/2026\/03\/Ray-Ashton.jpg');\" role=\"img\" aria-label=\"Ray Ashton\"><\/div>\n    <span>Written by <a href=\"https:\/\/kolanahealth.com\/ray-ashton\/\">Ray Ashton<\/a><\/span>\n  <\/div>\n  <span class=\"kh-byline-sep\">&mdash;<\/span>\n  <span>Updated April 4, 2026<\/span>\n<\/div>\n\n<!-- DISCLOSURE -->\n<div class=\"kh-disclosure\">\n  <strong>Editorial disclosure:<\/strong> Kolana Health provides this page for educational purposes only. We do not sell medication, dispense prescriptions, or direct readers to any pharmacy or commercial service. All decisions about medication access and financial assistance programs should be made in consultation with your healthcare provider.\n  <span class=\"kh-ep-link\"><a href=\"https:\/\/kolanahealth.com\/editorial-policy\/\">Read our editorial standards &rarr;<\/a><\/span>\n<\/div>\n\n\n<p>Biktarvy (bictegravir\/emtricitabine\/tenofovir alafenamide) is the most widely prescribed HIV treatment in the United States. But what you actually pay for it can range from $0 to over $4,000 a month &mdash; and the difference almost always comes down to your insurance design, not just the drug&rsquo;s listed price.<\/p>\n\n<p>This guide explains the factors that drive Biktarvy&rsquo;s cost, walks through common insurance scenarios, and covers every legitimate pathway to reduce your out-of-pocket expense. If you&rsquo;re facing a cost barrier, the most important thing is this: <strong>do not stop taking your medication without talking to your clinician first.<\/strong> There are options, and this page will help you understand them.<\/p>\n\n\n<!-- PRICE SNAPSHOT -->\n<div class=\"kh-snapshot\">\n  <div class=\"kh-snapshot-title\">Biktarvy Cost at a Glance &mdash; 2026<\/div>\n  <div class=\"kh-snapshot-grid\">\n    <div class=\"kh-snapshot-item\">\n      <div class=\"kh-snapshot-label\">List Price (WAC)<\/div>\n      <div class=\"kh-snapshot-value\">$4,216<small>\/mo<\/small><\/div>\n    <\/div>\n    <div class=\"kh-snapshot-item\">\n      <div class=\"kh-snapshot-label\">With Insurance + Copay Card<\/div>\n      <div class=\"kh-snapshot-value\">$0&ndash;$5<small>\/mo<\/small><\/div>\n    <\/div>\n    <div class=\"kh-snapshot-item\">\n      <div class=\"kh-snapshot-label\">Medicare + Extra Help<\/div>\n      <div class=\"kh-snapshot-value\">$4&ndash;$9<small>\/mo<\/small><\/div>\n    <\/div>\n    <div class=\"kh-snapshot-item\">\n      <div class=\"kh-snapshot-label\">Uninsured + Gilead PAP<\/div>\n      <div class=\"kh-snapshot-value\">$0<small>\/mo<\/small><\/div>\n    <\/div>\n  <\/div>\n  <div class=\"kh-snapshot-note\">List price effective January 1, 2026. Source: <a href=\"https:\/\/www.gileadpriceinfo.com\/biktarvy\">Gilead Price Info<\/a>. What you pay depends on your insurance plan, assistance programs, and pharmacy &mdash; see sections below.<\/div>\n<\/div>\n\n\n<!-- KEY FACTS -->\n<div class=\"kh-keyfacts\">\n  <div class=\"kh-keyfacts-title\">Key Factors That Determine Your Cost<\/div>\n  <ul>\n    <li><strong>Formulary tier<\/strong> &mdash; where your plan places Biktarvy (preferred brand, non-preferred, specialty)<\/li>\n    <li><strong>Deductible status<\/strong> &mdash; whether you&rsquo;ve met your annual deductible<\/li>\n    <li><strong>Copay vs. coinsurance<\/strong> &mdash; a flat dollar amount vs. a percentage of the drug&rsquo;s cost<\/li>\n    <li><strong>Copay accumulators<\/strong> &mdash; whether your plan counts manufacturer assistance toward your deductible<\/li>\n    <li><strong>Specialty pharmacy requirements<\/strong> &mdash; some plans mandate a specific pharmacy<\/li>\n    <li><strong>Prior authorization<\/strong> &mdash; whether your insurer requires clinical justification before covering it<\/li>\n    <li><strong>In-network vs. out-of-network<\/strong> &mdash; using plan-preferred providers and pharmacies<\/li>\n  <\/ul>\n<\/div>\n\n<div class=\"kh-callout kh-callout-danger\">\n  <p><strong>If you&rsquo;re facing an immediate gap in coverage:<\/strong> Contact your prescriber and insurer the same day. Ask about emergency or interim supply policies &mdash; many pharmacies and plans have provisions to prevent treatment interruption while coverage issues are resolved.<\/p>\n<\/div>\n\n\n<h2>Estimated Biktarvy Cost by Coverage Type<\/h2>\n\n<div class=\"kh-table-wrap\">\n<table>\n  <thead>\n    <tr>\n      <th>Coverage Situation<\/th>\n      <th>Estimated Monthly Cost<\/th>\n      <th>Key Notes<\/th>\n    <\/tr>\n  <\/thead>\n  <tbody>\n    <tr><td>Commercial insurance + Gilead copay card<\/td><td><strong>$0&ndash;$5<\/strong><\/td><td>Copay card covers up to $7,200\/year; ~98% of insured patients face no PA or step therapy<\/td><\/tr>\n    <tr><td>Commercial insurance, no copay card<\/td><td><strong>$50&ndash;$500+<\/strong><\/td><td>Depends on tier, deductible, coinsurance %; higher at start of plan year<\/td><\/tr>\n    <tr><td>Medicare Part D + Extra Help (LIS)<\/td><td><strong>$4&ndash;$9<\/strong><\/td><td>Low-Income Subsidy reduces cost; copay card cannot be used with Medicare<\/td><\/tr>\n    <tr><td>Medicare Part D, no Extra Help<\/td><td><strong>$50&ndash;$400+<\/strong><\/td><td>Varies by plan and coverage phase; costs drop in catastrophic phase<\/td><\/tr>\n    <tr><td>Medicaid<\/td><td><strong>$0&ndash;$3<\/strong><\/td><td>Covered in most states with minimal or no copay<\/td><\/tr>\n    <tr><td>Ryan White \/ ADAP<\/td><td><strong>$0<\/strong><\/td><td>Safety-net program for uninsured\/underinsured; eligibility varies by state<\/td><\/tr>\n    <tr><td>Gilead Patient Assistance (uninsured)<\/td><td><strong>$0<\/strong><\/td><td>Free medication for qualifying uninsured patients; income criteria apply<\/td><\/tr>\n    <tr><td>Uninsured, no assistance<\/td><td><strong>$3,800&ndash;$5,300+<\/strong><\/td><td>Full retail cash price; varies widely by pharmacy and location<\/td><\/tr>\n  <\/tbody>\n<\/table>\n<\/div>\n<p class=\"kh-table-note\">Estimates based on available data as of April 2026. Actual costs depend on individual plan design, pharmacy, and assistance eligibility. Sources: Gilead, CMS, NASTAD.<\/p>\n\n\n<h2>List Price, Cash Price, and Out-of-Pocket Cost Are Different<\/h2>\n\n<p>One of the most common sources of confusion is that people encounter very different numbers depending on context. These are three distinct concepts:<\/p>\n\n<p><strong>List price (WAC)<\/strong> is the wholesale acquisition cost set by Gilead Sciences. As of January 2026, Biktarvy&rsquo;s WAC is $4,216 per month. This is a benchmark used in negotiations between manufacturers, insurers, and pharmacy benefit managers &mdash; not what most patients pay. In January 2025, Gilead increased Biktarvy&rsquo;s WAC by approximately 5.9%. Source: <a href=\"https:\/\/www.pharmacytimes.com\/view\/ozempic-biktarvy-among-the-drugs-seeing-list-price-increases-at-the-start-of-2025\" target=\"_blank\" rel=\"noopener noreferrer\">Pharmacy Times<\/a>.<\/p>\n\n<p><strong>Cash price<\/strong> is what a pharmacy charges if you have no insurance coverage. This varies widely by pharmacy and location. Retail prices typically range from $3,800 to over $5,000 for a 30-day supply.<\/p>\n\n<p><strong>Out-of-pocket cost<\/strong> is what you personally pay after your insurance applies its coverage rules &mdash; formulary tier, deductible, copay or coinsurance, and any manufacturer assistance. This is the number that matters to you, and it can range from $0 to the full cash price depending on your specific situation.<\/p>\n\n<blockquote>Your out-of-pocket cost is a function of your plan design, not just the drug&rsquo;s price. Two people with different insurance plans can pay vastly different amounts for the same medication at the same pharmacy.<\/blockquote>\n\n<p>U.S. prescription drug prices are, on average, 2.56 times higher than in other developed countries. Source: <a href=\"https:\/\/www.rand.org\/pubs\/research_reports\/RRA788-1.html\" target=\"_blank\" rel=\"noopener noreferrer\">RAND Corporation<\/a>.<\/p>\n\n\n<h2>Common Insurance Scenarios and What to Expect<\/h2>\n\n<h3>If You Have Employer or Marketplace Insurance<\/h3>\n\n<p>Most commercial plans cover Biktarvy. According to manufacturer data, approximately 98% of insured patients can access Biktarvy without prior authorization or step therapy requirements. However, how much you pay depends on several plan-specific factors:<\/p>\n\n<ul>\n  <li><strong>Tiering:<\/strong> Biktarvy is typically placed on a specialty or non-preferred brand tier, which may mean coinsurance of 20&ndash;40% of the drug&rsquo;s cost until you hit your out-of-pocket maximum.<\/li>\n  <li><strong>Prior authorization or step therapy:<\/strong> A small percentage of plans require your prescriber to demonstrate medical necessity or show that you&rsquo;ve tried other medications first.<\/li>\n  <li><strong>Specialty pharmacy requirements:<\/strong> Many plans require specialty medications to be filled through a designated pharmacy. Using an out-of-network pharmacy may mean the cost isn&rsquo;t covered at all.<\/li>\n  <li><strong>Deductible reset (the &ldquo;January surprise&rdquo;):<\/strong> If your plan year starts in January, expect a cost spike early in the year before you&rsquo;ve met your deductible. Enrolling in Gilead&rsquo;s copay card before January can help bridge this gap.<\/li>\n<\/ul>\n\n<h3>Understanding Copay Accumulators (This May Affect You)<\/h3>\n\n<p>This is one of the most important &mdash; and least understood &mdash; factors that can dramatically increase your annual Biktarvy cost.<\/p>\n\n<p>A <strong>copay accumulator<\/strong> (also called a &ldquo;copay maximizer&rdquo; or &ldquo;accumulator adjustment program&rdquo;) is a policy adopted by some insurers and pharmacy benefit managers that <em>prevents<\/em> third-party payments &mdash; such as manufacturer copay cards &mdash; from counting toward your annual deductible or out-of-pocket maximum.<\/p>\n\n<p><strong>How it works in practice:<\/strong> Without a copay accumulator, Gilead&rsquo;s copay card pays toward your cost-sharing, and those payments reduce your deductible. With a copay accumulator, the copay card still covers your fills, but those payments don&rsquo;t count toward your deductible. Once the copay card&rsquo;s $7,200 annual cap is exhausted (often by mid-year), you suddenly face the full remaining deductible out of pocket.<\/p>\n\n<p><strong>What to do:<\/strong><\/p>\n<ul>\n  <li>Call your insurer and ask: <em>&ldquo;Does my plan use a copay accumulator or copay maximizer program?&rdquo;<\/em><\/li>\n  <li>Check your state&rsquo;s laws. As of early 2026, more than 19 states and Puerto Rico have enacted laws restricting copay accumulators for at least some drug classes.<\/li>\n  <li>If your plan uses an accumulator and your state hasn&rsquo;t banned it, the <a href=\"https:\/\/www.patientadvocate.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">Patient Advocate Foundation<\/a> can help you understand your options.<\/li>\n<\/ul>\n\n<h3>If You Have Medicare<\/h3>\n\n<p>Medicare Part D covers Biktarvy, but cost-sharing varies significantly by plan:<\/p>\n\n<ul>\n  <li>During the <strong>deductible phase<\/strong>, you pay the full negotiated price.<\/li>\n  <li>During the <strong>initial coverage phase<\/strong>, you pay your plan&rsquo;s copay or coinsurance.<\/li>\n  <li>After reaching the <strong>catastrophic coverage threshold<\/strong>, your cost-sharing drops significantly.<\/li>\n  <li>The <strong>Low-Income Subsidy (LIS \/ &ldquo;Extra Help&rdquo;)<\/strong> program reduces costs to $4&ndash;$9 per month for qualifying beneficiaries. Contact <a href=\"https:\/\/www.ssa.gov\/medicare\/part-d-extra-help\" target=\"_blank\" rel=\"noopener noreferrer\">Social Security Administration<\/a> to check eligibility.<\/li>\n<\/ul>\n\n<p><strong>Important:<\/strong> Gilead&rsquo;s copay card <em>cannot<\/em> be used with Medicare, Medicaid, or other government-funded insurance. However, nonprofit copay foundations may be able to help &mdash; see &ldquo;Nonprofit Copay Assistance&rdquo; below.<\/p>\n\n<div class=\"kh-callout kh-callout-info\">\n  <p><strong>Medicare negotiation update (January 2026):<\/strong> CMS selected Biktarvy for Medicare price negotiations under the Inflation Reduction Act &mdash; the first HIV medication ever chosen. Biktarvy cost Medicare approximately $3.9 billion for 101,000 beneficiaries. A negotiated &ldquo;Maximum Fair Price&rdquo; is expected to take effect in 2028. This does not affect current pricing for any patient. Source: <a href=\"https:\/\/www.positivelyaware.com\/articles\/biktarvy-among-15-drugs-facing-medicare-price-negotiations\" target=\"_blank\" rel=\"noopener noreferrer\">Positively Aware, Jan 2026<\/a>.<\/p>\n<\/div>\n\n<h3>If You Have Medicaid<\/h3>\n\n<p>Medicaid generally covers Biktarvy with minimal or no copay. Coverage rules and copay amounts vary by state. If you&rsquo;re on Medicaid and being asked to pay a significant amount, contact your state Medicaid office &mdash; this may be an error, or your plan may require prior authorization that hasn&rsquo;t been completed.<\/p>\n\n<h3>If You&rsquo;re Uninsured or Underinsured<\/h3>\n\n<p>Without insurance, Biktarvy&rsquo;s cash price is prohibitively high for most people. But there are multiple programs &mdash; from Gilead&rsquo;s own assistance to federal safety-net resources &mdash; that can bring your cost to $0. The dedicated guide below covers every option, step by step.<\/p>\n\n<div class=\"kh-crosslink\">\n  <strong>Full guide: Biktarvy cost without insurance<\/strong>\n  Every program that can bring your cost to $0 &mdash; Gilead PAP, ADAP, Ryan White, 340B, and nonprofit foundations &mdash; with eligibility details and how to apply. <a href=\"https:\/\/kolanahealth.com\/biktarvy-cost-without-insurance\/\">Biktarvy Cost Without Insurance &rarr;<\/a>\n<\/div>\n\n\n<h2>How to Lower Biktarvy Cost: Legitimate Pathways<\/h2>\n\n<h3>1. Manufacturer Patient Assistance and Copay Support<\/h3>\n\n<p>Gilead Sciences operates two distinct programs through <a href=\"https:\/\/www.gileadadvancingaccess.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">Gilead Advancing Access<\/a>:<\/p>\n\n<p><strong>Copay Card (commercially insured patients):<\/strong> Reduces your copay to as little as $0 per month, with an annual cap of $7,200 in assistance. Does not apply to Medicare, Medicaid, TRICARE, VA, or other government-funded plans.<\/p>\n\n<p><strong>Patient Assistance Program \/ PAP (uninsured patients):<\/strong> Provides Biktarvy at no cost. Eligibility is typically based on income (generally up to 500% of the federal poverty level). Enrollment lasts 12 months with an option to renew.<\/p>\n\n<p>To check eligibility or apply: call <strong>1-800-226-2056<\/strong> (multilingual support available) or enroll online at <a href=\"https:\/\/www.gileadadvancingaccess.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">GileadAdvancingAccess.com<\/a>.<\/p>\n\n<h3>2. Ryan White HIV\/AIDS Program and ADAP<\/h3>\n\n<p>The <a href=\"https:\/\/ryanwhite.hrsa.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">Ryan White HIV\/AIDS Program<\/a> is the largest federal program specifically for people living with HIV who are uninsured or underinsured. It funds clinics, support services, and the <strong>AIDS Drug Assistance Program (ADAP)<\/strong>.<\/p>\n\n<p>ADAP provides HIV medications at no cost or minimal copay to eligible individuals. To find your state&rsquo;s ADAP program: use the <a href=\"https:\/\/www.nastad.org\/adap-watch\" target=\"_blank\" rel=\"noopener noreferrer\">NASTAD ADAP locator<\/a> or call your local Ryan White clinic. HRSA maintains a <a href=\"https:\/\/findhivcare.hrsa.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">clinic locator<\/a> at findhivcare.hrsa.gov.<\/p>\n\n<h3>3. 340B Drug Pricing Program<\/h3>\n\n<p>The <strong>340B program<\/strong> requires drug manufacturers to sell outpatient drugs at significantly reduced prices to eligible healthcare organizations, including Ryan White grantees, federally qualified health centers (FQHCs), and disproportionate share hospitals.<\/p>\n\n<p>If you receive care at a 340B-eligible facility, you may benefit from lower medication costs &mdash; sometimes significantly lower than retail, even with insurance. Ask your clinic: <em>&ldquo;Does this facility participate in the 340B program, and can my prescription benefit from 340B pricing?&rdquo;<\/em> You can also search the <a href=\"https:\/\/www.hrsa.gov\/opa\/eligibility-and-registration\/340b-opais\" target=\"_blank\" rel=\"noopener noreferrer\">HRSA 340B database<\/a>.<\/p>\n\n<h3>4. Nonprofit Copay Assistance Foundations<\/h3>\n\n<p>Several independent nonprofits offer copay assistance for HIV medications. These are especially important for Medicare patients who cannot use Gilead&rsquo;s copay card:<\/p>\n\n<ul>\n  <li><strong><a href=\"https:\/\/www.patientadvocate.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">Patient Advocate Foundation (PAF)<\/a><\/strong> &mdash; copay relief program and free case management for insurance denials.<\/li>\n  <li><strong><a href=\"https:\/\/www.panfoundation.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">Patient Access Network (PAN) Foundation<\/a><\/strong> &mdash; grants for HIV treatment; helps with copays, deductibles, and insurance premiums.<\/li>\n  <li><strong><a href=\"https:\/\/www.healthwellfoundation.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">HealthWell Foundation<\/a><\/strong> &mdash; HIV\/AIDS fund for copay assistance when funding is available.<\/li>\n  <li><strong><a href=\"https:\/\/www.needymeds.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">NeedyMeds<\/a><\/strong> &mdash; aggregates assistance programs, discount drug cards, and free\/low-cost clinic locations.<\/li>\n<\/ul>\n\n<div class=\"kh-callout kh-callout-warn\">\n  <p><strong>Important:<\/strong> Nonprofit fund availability fluctuates based on donations. If one fund is currently closed, check others or apply for a waitlist. Your clinic&rsquo;s social worker can often help navigate applications.<\/p>\n<\/div>\n\n<h3>5. Insurance Appeals and Prior Authorization Support<\/h3>\n\n<ul>\n  <li>Ask your prescriber&rsquo;s office to submit prior authorization with supporting documentation &mdash; lab results, treatment history, and relevant DHHS clinical guidelines.<\/li>\n  <li>If denied, request a <strong>written explanation<\/strong> of the denial reason.<\/li>\n  <li>File a formal appeal. Most plans must process appeals within 30&ndash;60 days.<\/li>\n  <li>If the internal appeal is denied, you may have the right to an <strong>external review<\/strong> by an independent third party &mdash; a federal right under the ACA for most commercial plans.<\/li>\n  <li>Gilead&rsquo;s Advancing Access program offers prior authorization support &mdash; call 1-800-226-2056.<\/li>\n<\/ul>\n\n<h3>6. Discuss Clinically Appropriate Alternatives With Your Clinician<\/h3>\n\n<p>If Biktarvy&rsquo;s cost remains a barrier after exhausting other options, your HIV specialist may be able to recommend an alternative regimen with lower cost-sharing on your specific plan.<\/p>\n\n<div class=\"kh-callout kh-callout-warn\">\n  <p><strong>Important:<\/strong> HIV regimen choice is highly individualized. It depends on your resistance profile, tolerability, kidney and bone health, drug interactions, and treatment history. Always let your clinician guide this decision &mdash; do not switch or stop medications on your own.<\/p>\n<\/div>\n\n<h3>7. Pharmacy Benefit Optimization<\/h3>\n\n<ul>\n  <li><strong>Use in-network pharmacies.<\/strong> Filling at an out-of-network pharmacy can mean paying the full cash price.<\/li>\n  <li><strong>Check for specialty pharmacy requirements.<\/strong> Many plans mandate specialty drugs be filled through a designated pharmacy.<\/li>\n  <li><strong>Ask about mail-order options.<\/strong> Some plans offer lower cost-sharing for 90-day mail-order fills.<\/li>\n  <li><strong>Compare plan options during open enrollment<\/strong> for formulary placement and specialty drug cost-sharing for Biktarvy specifically.<\/li>\n  <li><strong>Confirm your plan&rsquo;s preferred pharmacy list<\/strong> by calling the number on the back of your insurance card.<\/li>\n<\/ul>\n\n\n<h2>Is There a Generic Version of Biktarvy?<\/h2>\n\n<p>As of 2026, <strong>no FDA-approved generic Biktarvy exists in the United States<\/strong>. Gilead Sciences holds U.S. patent protection on bictegravir, with patent expiry not before <strong>November 8, 2036<\/strong>. Source: <a href=\"https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/index.cfm\" target=\"_blank\" rel=\"noopener noreferrer\">FDA Orange Book<\/a>.<\/p>\n\n<p>A &ldquo;generic&rdquo; drug, in the FDA&rsquo;s regulatory framework, is a medication approved through an Abbreviated New Drug Application (ANDA) demonstrating bioequivalence to the brand-name product. Until such approval is granted, no U.S. pharmacy can legally dispense a generic version.<\/p>\n\n<p>Generic versions of Biktarvy&rsquo;s active ingredients do exist in some countries under Gilead&rsquo;s voluntary licensing agreements through the <a href=\"https:\/\/medicinespatentpool.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">Medicines Patent Pool<\/a>. These generics are manufactured for distribution in designated low- and middle-income countries &mdash; they are not FDA-approved and cannot legally be distributed in the U.S.<\/p>\n\n\n<h2>A Note on Medications From Outside the U.S.<\/h2>\n\n<p>Some patients facing high costs consider obtaining medications from outside the United States. There are important safety and legal considerations:<\/p>\n\n<ul>\n  <li>The FDA states that in most circumstances, it is <strong>illegal for individuals to import non-FDA-approved drugs<\/strong> into the United States. The agency maintains a discretionary enforcement policy, but this does not create a legal right to import. Source: <a href=\"https:\/\/www.fda.gov\/industry\/import-program-food-and-drug-administration\/personal-importation\" target=\"_blank\" rel=\"noopener noreferrer\">FDA Personal Importation<\/a>.<\/li>\n  <li>Counterfeit and substandard medications are a documented risk in unverified supply chains. The FDA has issued <a href=\"https:\/\/www.fda.gov\/consumers\/consumer-updates\/how-buy-medicines-safely-online-pharmacy\" target=\"_blank\" rel=\"noopener noreferrer\">consumer guidance<\/a> on the risks of purchasing medications from unverified online sources.<\/li>\n  <li>If you switch to any medication not obtained through your usual care pathway, discuss this with your clinician so they can monitor your viral load and treatment response.<\/li>\n<\/ul>\n\n<p>This guide does not provide instructions for obtaining medications from outside the U.S., nor recommend any specific sources. If cost is driving you to consider this route, the assistance programs described above may be able to help first.<\/p>\n\n\n<h2>Frequently Asked Questions<\/h2>\n\n<div class=\"kh-faq\">\n\n  <div class=\"kh-faq-item\">\n    <div class=\"kh-faq-q\">How much does Biktarvy cost without insurance in 2026?<\/div>\n    <p class=\"kh-faq-a\">Biktarvy&rsquo;s list price is $4,216 per month as of January 2026, with retail cash prices typically ranging from $3,800 to over $5,000. Most uninsured patients qualify for programs that reduce the cost to $0. See the full guide: <a href=\"https:\/\/kolanahealth.com\/biktarvy-cost-without-insurance\/\">Biktarvy cost without insurance: every program, step by step &rarr;<\/a><\/p>\n  <\/div>\n\n  <div class=\"kh-faq-item\">\n    <div class=\"kh-faq-q\">How much does Biktarvy cost with insurance?<\/div>\n    <p class=\"kh-faq-a\">With commercial insurance and Gilead&rsquo;s copay card, most patients pay $0 to $5 per month. Without the copay card, costs depend on your plan&rsquo;s formulary tier, deductible status, and coinsurance percentage. Medicare patients with Extra Help may pay $4 to $9 per month.<\/p>\n  <\/div>\n\n  <div class=\"kh-faq-item\">\n    <div class=\"kh-faq-q\">Why did my Biktarvy copay increase this month?<\/div>\n    <p class=\"kh-faq-a\">Common causes include annual deductible reset (especially in January), a formulary tier change by your insurer, or the adoption of a copay accumulator program that prevents manufacturer assistance from counting toward your deductible. Contact your insurer to confirm.<\/p>\n  <\/div>\n\n  <div class=\"kh-faq-item\">\n    <div class=\"kh-faq-q\">What is prior authorization for Biktarvy and how long does it take?<\/div>\n    <p class=\"kh-faq-a\">Prior authorization is a requirement by some insurers for your prescriber to submit clinical justification before the plan covers Biktarvy. Standard decisions typically take 5 to 15 business days. Urgent requests may be processed within 24 to 72 hours. About 98% of insured patients can access Biktarvy without prior authorization or step therapy.<\/p>\n  <\/div>\n\n  <div class=\"kh-faq-item\">\n    <div class=\"kh-faq-q\">How do Biktarvy copay cards work and who is eligible?<\/div>\n    <p class=\"kh-faq-a\">Gilead&rsquo;s Advancing Access copay card reduces out-of-pocket costs for commercially insured patients, typically to $0 per month with a $7,200 annual cap. It does not apply to Medicare, Medicaid, TRICARE, or other government-funded insurance. Be aware that some plans use copay accumulator programs that prevent this assistance from counting toward your deductible.<\/p>\n  <\/div>\n\n  <div class=\"kh-faq-item\">\n    <div class=\"kh-faq-q\">What is a copay accumulator and how does it affect my Biktarvy cost?<\/div>\n    <p class=\"kh-faq-a\">A copay accumulator prevents third-party payments (like manufacturer copay cards) from counting toward your deductible or out-of-pocket maximum. After the copay card&rsquo;s $7,200 annual cap is exhausted, you may owe your full remaining deductible. More than 19 states have enacted laws restricting these programs. Ask your insurer if your plan uses one.<\/p>\n  <\/div>\n\n  <div class=\"kh-faq-item\">\n    <div class=\"kh-faq-q\">What if my insurance denies coverage for Biktarvy?<\/div>\n    <p class=\"kh-faq-a\">Request a written explanation of the denial, then ask your prescriber&rsquo;s office to file a formal appeal with lab results, treatment history, and clinical guidelines. Most plans must resolve appeals within 30&ndash;60 days. The <a href=\"https:\/\/www.patientadvocate.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">Patient Advocate Foundation<\/a> offers free case management to help.<\/p>\n  <\/div>\n\n  <div class=\"kh-faq-item\">\n    <div class=\"kh-faq-q\">Can I safely stop taking Biktarvy if I cannot afford it?<\/div>\n    <p class=\"kh-faq-a\"><strong>Do not stop antiretroviral therapy without speaking with your clinician.<\/strong> Interrupting treatment can lead to viral rebound, immune decline, and drug resistance. If cost is a barrier, contact your prescriber immediately &mdash; emergency fills and assistance programs can often be arranged within days.<\/p>\n  <\/div>\n\n  <div class=\"kh-faq-item\">\n    <div class=\"kh-faq-q\">Is there a generic version of Biktarvy in the United States?<\/div>\n    <p class=\"kh-faq-a\">No. As of 2026, no FDA-approved generic exists. Patent expiry is not before November 2036. Generic versions exist in some countries under Gilead&rsquo;s voluntary licensing program, but are not approved for U.S. distribution.<\/p>\n  <\/div>\n\n  <div class=\"kh-faq-item\">\n    <div class=\"kh-faq-q\">What if I lose my job and health insurance?<\/div>\n    <p class=\"kh-faq-a\">Contact your state ADAP program and local Ryan White clinic immediately &mdash; these exist specifically for this situation. You may also qualify for Gilead&rsquo;s PAP for uninsured individuals. COBRA continuation may be available but is often expensive. Use <a href=\"https:\/\/findhivcare.hrsa.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">findhivcare.hrsa.gov<\/a> to locate your nearest clinic.<\/p>\n  <\/div>\n\n  <div class=\"kh-faq-item\">\n    <div class=\"kh-faq-q\">Will the Medicare price negotiation lower my Biktarvy cost?<\/div>\n    <p class=\"kh-faq-a\">Biktarvy was selected for Medicare price negotiations in January 2026 &mdash; the first HIV drug ever chosen. A negotiated price applies only to Medicare Part D and is expected in 2028 at the earliest. It will not affect commercial insurance or uninsured cash prices.<\/p>\n  <\/div>\n\n  <div class=\"kh-faq-item\">\n    <div class=\"kh-faq-q\">Can I change pharmacies to lower my Biktarvy cost?<\/div>\n    <p class=\"kh-faq-a\">Possibly. Switching to an in-network or plan-preferred pharmacy can reduce your cost, and some plans offer lower cost-sharing for 90-day mail-order fills. Call your insurer to confirm which pharmacies are preferred. If you receive care at a 340B-eligible clinic, ask if your prescription can be filled through their pharmacy.<\/p>\n  <\/div>\n\n  <div class=\"kh-faq-item\">\n    <div class=\"kh-faq-q\">What is 340B pricing and can it lower my Biktarvy cost?<\/div>\n    <p class=\"kh-faq-a\">The 340B program requires manufacturers to sell drugs at reduced prices to eligible safety-net providers, including Ryan White clinics and FQHCs. If you receive care at a participating facility, you may benefit from lower medication costs. Ask your clinic if they participate.<\/p>\n  <\/div>\n\n  <div class=\"kh-faq-item\">\n    <div class=\"kh-faq-q\">Are there nonprofit foundations that help pay for Biktarvy?<\/div>\n    <p class=\"kh-faq-a\">Yes. The Patient Advocate Foundation, PAN Foundation, and HealthWell Foundation all offer HIV copay assistance programs. These are especially important for Medicare patients who cannot use Gilead&rsquo;s copay card. Fund availability fluctuates &mdash; if one is closed, check others or apply for a waitlist.<\/p>\n  <\/div>\n\n<\/div>\n\n\n<!-- WHAT TO DO TODAY -->\n<h2>What to Do Today<\/h2>\n\n<div class=\"kh-checklist\">\n  <div class=\"kh-checklist-title\">Your Next Steps<\/div>\n  <ul>\n    <li>Call your insurer: confirm Biktarvy&rsquo;s formulary tier, copay, and whether your plan uses a copay accumulator<\/li>\n    <li>Ask if a specialty pharmacy is required under your plan<\/li>\n    <li>If prior authorization is needed, ask your prescriber&rsquo;s office to initiate it<\/li>\n    <li>Check eligibility for Gilead&rsquo;s copay card (insured) or PAP (uninsured) &mdash; 1-800-226-2056<\/li>\n    <li>If you have Medicare, check eligibility for Extra Help at <a href=\"https:\/\/www.ssa.gov\/medicare\/part-d-extra-help\" target=\"_blank\" rel=\"noopener noreferrer\">ssa.gov<\/a><\/li>\n    <li>Locate your state&rsquo;s ADAP program at <a href=\"https:\/\/www.nastad.org\/adap-watch\" target=\"_blank\" rel=\"noopener noreferrer\">nastad.org\/adap-watch<\/a><\/li>\n    <li>Find a nearby Ryan White clinic at <a href=\"https:\/\/findhivcare.hrsa.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">findhivcare.hrsa.gov<\/a><\/li>\n    <li>Ask your clinic about 340B program eligibility<\/li>\n    <li>Check nonprofit foundations: <a href=\"https:\/\/www.patientadvocate.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">PAF<\/a>, <a href=\"https:\/\/www.panfoundation.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">PAN<\/a>, <a href=\"https:\/\/www.healthwellfoundation.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">HealthWell<\/a><\/li>\n    <li><strong>Do not interrupt your medication without medical guidance<\/strong><\/li>\n  <\/ul>\n<\/div>\n\n\n<!-- HOW WE REVIEWED -->\n<div class=\"kh-reviewed\">\n  <div class=\"kh-reviewed-byline\">\n    <div class=\"kh-byline-pair\">\n      <div class=\"kh-avatar kh-avatar-36\" style=\"background-image:url('https:\/\/kolanahealth.com\/wp-content\/uploads\/2026\/03\/Dr-Neha-Mishra.jpg');\" role=\"img\" aria-label=\"Dr. Neha Mishra, MD\"><\/div>\n      <span>Medically reviewed by <a href=\"https:\/\/kolanahealth.com\/dr-neha-mishra\/\">Dr. Neha Mishra, MD<\/a><\/span>\n    <\/div>\n    <span class=\"kh-byline-sep\">&mdash;<\/span>\n    <div class=\"kh-byline-pair\">\n      <div class=\"kh-avatar kh-avatar-36\" style=\"background-image:url('https:\/\/kolanahealth.com\/wp-content\/uploads\/2026\/03\/Ray-Ashton.jpg');\" role=\"img\" aria-label=\"Ray Ashton\"><\/div>\n      <span>Written by <a href=\"https:\/\/kolanahealth.com\/ray-ashton\/\">Ray Ashton<\/a><\/span>\n    <\/div>\n    <span class=\"kh-byline-sep\">&mdash;<\/span>\n    <span>Updated April 4, 2026<\/span>\n  <\/div>\n  <div class=\"kh-reviewed-body\">\n    <p><strong>How we reviewed this article:<\/strong><\/p>\n    <p>Kolana Health follows strict sourcing guidelines and relies on peer-reviewed studies, government agencies (FDA, CMS, HRSA), academic research institutions, and medical associations (DHHS, IDSA). We use only credible, verifiable sources. Learn more in our <a href=\"https:\/\/kolanahealth.com\/editorial-policy\/\">editorial policy<\/a>.<\/p>\n    <span class=\"kh-ep-link\"><a href=\"https:\/\/kolanahealth.com\/editorial-policy\/\">Read our editorial policy &rarr;<\/a><\/span>\n  <\/div>\n<\/div>\n\n\n<!-- REFERENCES -->\n<div class=\"kh-refs\">\n  <h2>Sources &amp; References<\/h2>\n  <ol>\n    <li>FDA Biktarvy Prescribing Information (2025): <a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/210251s023lbl.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">accessdata.fda.gov<\/a><\/li>\n    <li>Gilead Price Info &mdash; Biktarvy WAC: <a href=\"https:\/\/www.gileadpriceinfo.com\/biktarvy\" target=\"_blank\" rel=\"noopener noreferrer\">gileadpriceinfo.com<\/a><\/li>\n    <li>Gilead Advancing Access Program: <a href=\"https:\/\/www.gileadadvancingaccess.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">gileadadvancingaccess.com<\/a><\/li>\n    <li>Pharmacy Times &mdash; 2025 Price Increases: <a href=\"https:\/\/www.pharmacytimes.com\/view\/ozempic-biktarvy-among-the-drugs-seeing-list-price-increases-at-the-start-of-2025\" target=\"_blank\" rel=\"noopener noreferrer\">pharmacytimes.com<\/a><\/li>\n    <li>CMS &mdash; Biktarvy Selected for Medicare Negotiation (Jan 2026): <a href=\"https:\/\/www.positivelyaware.com\/articles\/biktarvy-among-15-drugs-facing-medicare-price-negotiations\" target=\"_blank\" rel=\"noopener noreferrer\">positivelyaware.com<\/a><\/li>\n    <li>RAND Corporation &mdash; International Drug Price Comparisons: <a href=\"https:\/\/www.rand.org\/pubs\/research_reports\/RRA788-1.html\" target=\"_blank\" rel=\"noopener noreferrer\">rand.org<\/a><\/li>\n    <li>Ryan White HIV\/AIDS Program: <a href=\"https:\/\/ryanwhite.hrsa.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">ryanwhite.hrsa.gov<\/a><\/li>\n    <li>NASTAD ADAP Watch: <a href=\"https:\/\/www.nastad.org\/adap-watch\" target=\"_blank\" rel=\"noopener noreferrer\">nastad.org<\/a><\/li>\n    <li>HRSA &mdash; Find HIV Care Locator: <a href=\"https:\/\/findhivcare.hrsa.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">findhivcare.hrsa.gov<\/a><\/li>\n    <li>HRSA &mdash; 340B Drug Pricing Program: <a href=\"https:\/\/www.hrsa.gov\/opa\/eligibility-and-registration\/340b-opais\" target=\"_blank\" rel=\"noopener noreferrer\">hrsa.gov<\/a><\/li>\n    <li>FDA Orange Book &mdash; Biktarvy Patent Info: <a href=\"https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/index.cfm\" target=\"_blank\" rel=\"noopener noreferrer\">accessdata.fda.gov<\/a><\/li>\n    <li>FDA &mdash; Personal Importation Policy: <a href=\"https:\/\/www.fda.gov\/industry\/import-program-food-and-drug-administration\/personal-importation\" target=\"_blank\" rel=\"noopener noreferrer\">fda.gov<\/a><\/li>\n    <li>Social Security &mdash; Medicare Extra Help: <a href=\"https:\/\/www.ssa.gov\/medicare\/part-d-extra-help\" target=\"_blank\" rel=\"noopener noreferrer\">ssa.gov<\/a><\/li>\n    <li>Patient Advocate Foundation: <a href=\"https:\/\/www.patientadvocate.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">patientadvocate.org<\/a><\/li>\n    <li>Patient Access Network Foundation: <a href=\"https:\/\/www.panfoundation.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">panfoundation.org<\/a><\/li>\n    <li>HealthWell Foundation: <a href=\"https:\/\/www.healthwellfoundation.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">healthwellfoundation.org<\/a><\/li>\n    <li>NeedyMeds: <a href=\"https:\/\/www.needymeds.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">needymeds.org<\/a><\/li>\n    <li>Medicines Patent Pool &mdash; Gilead Licensing: <a href=\"https:\/\/medicinespatentpool.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">medicinespatentpool.org<\/a><\/li>\n  <\/ol>\n<\/div>\n\n<\/div><!-- \/.kh -->\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Medically reviewed by Dr. Neha Mishra, MD &mdash; Written by Ray Ashton &mdash; Updated April 4, 2026 Editorial disclosure: Kolana [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-7","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.kalonahealth.com\/index.php?rest_route=\/wp\/v2\/pages\/7","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.kalonahealth.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.kalonahealth.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.kalonahealth.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.kalonahealth.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7"}],"version-history":[{"count":2,"href":"https:\/\/www.kalonahealth.com\/index.php?rest_route=\/wp\/v2\/pages\/7\/revisions"}],"predecessor-version":[{"id":19,"href":"https:\/\/www.kalonahealth.com\/index.php?rest_route=\/wp\/v2\/pages\/7\/revisions\/19"}],"wp:attachment":[{"href":"https:\/\/www.kalonahealth.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}